New Developments in the Treatment of Schizophrenia: An Expert Roundtable
International Journal of Neuropsychopharmacology · 31.05.2023 · 26 (5) · 322-330
DOI: 10.1093/ijnp/pyad011 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Neuropsychopharmacology, online erschienen am 18.03.2023. Verfasst von Joshua T Kantrowitz und 3 weiteren Autor:innen. Beteiligte Einrichtung: Area Psychosis, New York State Psychiatric Institute, New York, New York, USA. Hauptthemen laut MEDLINE: Antipsychotic Agents, Schizophrenia, Clozapine. Die Arbeit wurde bisher 50-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Schizophrenia is a disabling disorder that profoundly affects functioning and quality of life. While available antipsychotics have improved outcomes for patients with schizophrenia, they are relatively ineffective for negative and cognitive symptoms and are associated with a range of troublesome side effects. A significant unmet medical need for more effective and better-tolerated therapies remains.
Methods
A roundtable consisting of 4 experts in the treatment of patients with schizophrenia convened to discuss the current treatment landscape, unmet needs from patient and societal perspectives, and the potential of emerging therapies with novel mechanisms of action (MOAs).
Results
Key areas of unmet need include optimal implementation of available treatments, effective treatment of negative and cognitive symptoms, improvements in medication adherence, novel MOAs, avoidance of postsynaptic dopamine blockade–related adverse effects, and individualized approaches to treatment. With the possible exception of clozapine, all currently available antipsychotics primarily act by blocking dopamine D2 receptors. Agents with novel MOAs are urgently needed to effectively target the full range of symptoms in schizophrenia and facilitate an individualized treatment approach. Discussion focused on promising novel MOAs that have demonstrated potential in phase 2 and 3 trials include muscarinic receptor agonism, trace amine-associated receptor 1 agonism, serotonin receptor antagonism/inverse agonism, and glutamatergic modulation.
Conclusions
Results from early clinical trials of agents with novel MOAs are encouraging, particularly for muscarinic and trace amine-associated receptor 1 agonists. These agents offer renewed hope for meaningful improvement in the management of patients with schizophrenia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Area Psychosis, New York State Psychiatric Institute, New York, New York, USA.
- Schizophrenia Research, Nathan Kline Institute, Orangeburg, New York, USA.
- Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, New York, USA.
- Department of Psychiatry Research, The Zucker Hillside Hospital, Glen Oaks, New York, USA.
- Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, USA.
- Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin Berlin, Berlin, Germany.
ORCID-Profile: Joshua T Kantrowitz
Zitieren
APA
Kantrowitz, J. T., Correll, C. U., Jain, R., & Cutler, A. J. (2023). New Developments in the Treatment of Schizophrenia: An Expert Roundtable. International Journal of Neuropsychopharmacology, 26(5), 322-330. https://doi.org/10.1093/ijnp/pyad011
Vancouver
Kantrowitz JT, Correll CU, Jain R, Cutler AJ. New Developments in the Treatment of Schizophrenia: An Expert Roundtable. International Journal of Neuropsychopharmacology. 2023;26(5):322-330. doi:10.1093/ijnp/pyad011
BibTeX
@article{Kantrowitz2023,
author = {Kantrowitz, Joshua T and Correll, Christoph U and Jain, Rakesh and Cutler, Andrew J},
title = {New Developments in the Treatment of Schizophrenia: An Expert Roundtable},
journal = {International Journal of Neuropsychopharmacology},
year = {2023},
volume = {26},
number = {5},
pages = {322--330},
doi = {10.1093/ijnp/pyad011}
}
EUVIMED